Abstract: Methods for identifying HERV-derived T cell epitopes associated with cancer, and peptides that are or that include epitopes identified by the methods, expression vectors encoding the peptides, cytotoxic T lymphocytes (CTLs) of a subject treated with the peptides or vectors and engineered T cells expressing T-cell receptors recognizing the peptides. Also, the peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular the use of the peptides, expression vectors, CTLs or engineered T cells for use in preventing or treating cancer in a subject in need thereof.

Abstract: Computer device (33) for determining an appropriate positioning of an instrumentation on a target bone area (200) according to a relative positioning (42) of said instrumentation to said target bone area defined by a surgical planning (32), said device comprising—an interface for receiving from a 3D camera (31) a depth map (41) of a captured scene (310) comprising at least said target bone area; —computing means for determining a position element of said target bone area from said depth map; determining a second positioned shape (442) of said target bone area according to said relative positioning (42), and determining data (43) representative of said appropriate positioning on the base of said second positioned shape (442) and said position element; —a human-machine interface for providing said data.

Abstract: The present disclosure relates to the identification of a biomarker, consisting in a circulating miRNA, suitable for use in the diagnosis and prognosis of high-grade serous ovarian carcinoma (HGSOC), and to diagnostic kits for use in such diagnosis.

Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

Abstract: A scanning dynamic collimator device (SDD) for minibeam production. The SDD includes a single slit collimator being mounted on a support. The SDD is arranged to translate the collimator in a plane perpendicular to a plane whereby the single slit extends and/or in a direction parallel to the plane whereby the single slit extends and/or to rotate the collimator relative to a rotation axis parallel to the plane whereby the single slit extends and to tilt the collimator relative to a predefined reference axis and/or relative to a point comprised in the single slit.

Abstract: Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.

Abstract: A method for manufacturing a detector of a first and a second incident ionizing radiation including determining the abscissa em of a point of intersection between a first and a second curve, with the first and second curves representing the evolution of the number of photons or electrical charges generated per second by a transducing material as a function of the total thickness of an amplifying material when the transducing material is irradiated, through this thickness of transducing material, by the first and second incident ionizing radiation, respectively; then selecting the total thickness of amplifying material between 0.9 em and 1.1 em and producing the detector with the selected thickness of amplifying material.

Abstract: The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.

Abstract: The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

Abstract: The disclosure is directed at providing molecular tools and methods for transgenes integration in the genome of host cells, in particular tools and method enabling a transposition-dependent expression of the transgene, thereby facilitating identification and selection of effectively transformed hosts.

Abstract: A process for preparing a modified heat-treated platelet pellet lysate, said process comprising the steps of: a) Providing a platelet pellet lysate, b) Heat-treating the platelet pellet lysate at a temperature of 55° C. to 65° C. during 20 to 40 minutes, c) Purifying the heat-treated platelet pellet lysate of step b) so as to obtain a modified heat treated platelet pellet lysate having a total protein content of less than 70% of the total protein content of the platelet pellet lysate of step a).

Abstract: Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).

Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas catoniae compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas catoniae in a biological sample obtained from said subject.

Abstract: A technique for moving various objects such as cells and particles of hydrogel or a compressible material, suspended in a fluid, so as to form a layered structure akin to human organ tissue. A standing sound wave is propagated through the fluid so as to position the cells on a pressure node and the particles on a pressure antinode. As such, the cells have a positive acoustic contrast relative to the fluid, while the particles have a negative acoustic contrast relative to the fluid.

Abstract: A new peptide and its use as a vector for the transport of molecules after conjugation through cellular barriers for the diagnosis, prognosis or treatment of pathologies of the central nervous system (CNS).

Abstract: The present invention relates to a method for analyzing the platelets present in a blood sample, said method comprises the steps of (a) adding to said sample a ligand which binds to the MCH I coupled to a fluorochrome, (b) measuring the mean fluorescence intensity of the platelets (MFIplatelets) with a flow cytometer and c) measuring the mean “Forward Scatter” parameter (FSC) with said flow cytometer and determining the MFIplatelets/FSC ratio. The invention also relates to an in vitro method for diagnosing a peripheral or central thrombocytopenia in a subject.

Abstract: Disclosed is a device including a detector producing a signal depending on variations of the pupil diameter of an eye of a subject, a display for presenting, to the subject, a light pattern subdivided into a plurality of regions, and an analyzer receiving the signal of the detector and analyzing the frequential content thereof. The display is controlled such that each region has a light intensity modulated at a respective modulation frequency, the modulation frequencies being different from one region to the next.

Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.

Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.